135 related articles for article (PubMed ID: 19452535)
21. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.
Santin AD; Zhan F; Cane' S; Bellone S; Palmieri M; Thomas M; Burnett A; Roman JJ; Cannon MJ; Shaughnessy J; Pecorelli S
Br J Cancer; 2005 Apr; 92(8):1561-73. PubMed ID: 15785748
[TBL] [Abstract][Full Text] [Related]
22. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.
Cross SN; Cocco E; Bellone S; Anagnostou VK; Brower SL; Richter CE; Siegel ER; Schwartz PE; Rutherford TJ; Santin AD
Am J Obstet Gynecol; 2010 Aug; 203(2):162.e1-8. PubMed ID: 20417484
[TBL] [Abstract][Full Text] [Related]
23. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
[TBL] [Abstract][Full Text] [Related]
24. [Advances in the treatment of uterine sarcoma].
Pan L; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1999 Nov; 34(11):702-4. PubMed ID: 11479953
[No Abstract] [Full Text] [Related]
25. [Results of the treatment of adenocarcinoma of the endometrium].
Vera González JA; Saavedra Macaya R; Saavedra Yáñez F; Ossandón Guzmán M
Rev Chil Obstet Ginecol; 1985; 50(4):305-16. PubMed ID: 3843281
[No Abstract] [Full Text] [Related]
26. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?
Santin AD
Gynecol Oncol; 2003 Mar; 88(3):263-5. PubMed ID: 12648572
[No Abstract] [Full Text] [Related]
27. Pulmonary fibrosis after pegylated liposomal Doxorubicin in a patient with uterine papillary serous carcinoma.
Nevadunsky NS; Mbagwu C; Mizrahi N; Burton E; Goldberg GL
J Clin Oncol; 2013 Apr; 31(10):e167-9. PubMed ID: 23358980
[No Abstract] [Full Text] [Related]
28. Scalp metastasis of a serous ovarian cancer.
Matsui H; Suzuka K; Yamazawa K; Tanaka N; Mitsuhashi A; Seki K; Sekiya S
Acta Obstet Gynecol Scand; 2002 Jun; 81(6):577-8. PubMed ID: 12047318
[No Abstract] [Full Text] [Related]
29. [Recent problems in the diagnosis and therapy of carcinoma of the endometrium].
Nishiya I; Satoh K
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Sep; 39(9):1665-70. PubMed ID: 3681065
[No Abstract] [Full Text] [Related]
30. Is micropapillary serous carcinoma for real?
Gershenson DM
Cancer; 2002 Aug; 95(4):677-80. PubMed ID: 12209709
[No Abstract] [Full Text] [Related]
31. Patients having prophylactic surgery for family history or known genetic mutations: why save the uterus?
Geisler JP
Gynecol Oncol; 2007 Mar; 104(3):780-1. PubMed ID: 17240434
[No Abstract] [Full Text] [Related]
32. Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function.
Hashimoto H; Kojima A; Sudo T; Ohki N; Yamaguchi S; Mikami Y; Ito M; Nishimura R
Hum Cell; 2008 Aug; 21(3):64-9. PubMed ID: 18667022
[TBL] [Abstract][Full Text] [Related]
33. [Chemotherapy in the treatment of the early relapse of cervical cancer].
Popiela A; Mazurec M; Karmowski A
Ginekol Pol; 1998 May; 69(5):226-31. PubMed ID: 9695317
[TBL] [Abstract][Full Text] [Related]
34. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma.
Abramovich D; Markman M; Kennedy A; Webster K; Belinson J
J Cancer Res Clin Oncol; 1999 Dec; 125(12):697-8. PubMed ID: 10592103
[TBL] [Abstract][Full Text] [Related]
35. Uterine papillary serous carcinoma revisited.
Hendrickson MR; Longacre TA; Kempson RL
Gynecol Oncol; 1994 Sep; 54(3):261-3. PubMed ID: 8088601
[No Abstract] [Full Text] [Related]
36. Familial and hormonal risk factors for papillary serous uterine cancer.
Elit L; Pal T; Goshen R; Jernström H; Ackerman I; Fyles A; Carey M; Mitchell M; Aube J; Narod SA
Eur J Gynaecol Oncol; 2002; 23(3):187-90. PubMed ID: 12094951
[TBL] [Abstract][Full Text] [Related]
37. [Initial treatment for uterine neoplasm].
Otsuki T; Ito K; Yaegashi N
Gan To Kagaku Ryoho; 2009 Feb; 36(2):215-9. PubMed ID: 19263609
[No Abstract] [Full Text] [Related]
38. [Treatment for recurrent uterine cancer].
Sagae S; Sugimura M; Nagata M
Gan To Kagaku Ryoho; 2009 Feb; 36(2):220-3. PubMed ID: 19263610
[No Abstract] [Full Text] [Related]
39. Targeted therapy in the treatment of uterine serous carcinoma.
Schwab CL; Santin AD
Pharmacogenomics; 2015 Jan; 16(2):97-9. PubMed ID: 25616096
[No Abstract] [Full Text] [Related]
40. Bilateral inflammatory breast involvement as the first site of relapse of ovarian carcinoma.
Oksüzoğlu B; Güler N; Köse F
Am J Clin Oncol; 2001 Apr; 24(2):211. PubMed ID: 11319301
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
